Related Experiment Video

Updated: Jan 9, 2026

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.2K

Effectiveness of a Cardiovascular Management System on Triple Risk Factor Control in High-Risk Older Adults: Protocol

Yan Wang1, Lei Su2, Jingyi Xiao1

  • 1Centre of Health Management, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.

JMIR Research Protocols
|December 9, 2025
PubMed

Insights

This randomized trial will assess the CardioCare system for managing cardiovascular disease risk factors in high-risk adults. It aims to improve triple risk factor control, enhancing patient outcomes and healthcare strategies.

Area of Science:

  • Cardiovascular disease (CVD) research
  • Digital health interventions
  • Public health management

Background:

  • Cardiovascular disease (CVD) is a major health concern in China.
  • Current public health programs offer limited post-screening management for CVD risk factors.
  • The CardioCare system offers a digital solution for cardiovascular risk management.

Purpose of the Study:

  • To evaluate the CardioCare system's effectiveness in achieving triple risk factor control (blood pressure, lipids, glycemia) in high-risk adults.
  • To assess secondary outcomes including CVD risk, clinical parameters, medication adherence, lifestyle changes, and system usability.
  • To determine the cost-effectiveness of the CardioCare intervention.

Main Methods:

  • A single-center, superiority randomized controlled trial with 1:1 allocation.
  • 300 adults aged ≥50 years with >10% 10-year CVD risk will be recruited.
  • Intervention group receives CardioCare system (risk stratification, personalized messages, cardiologist oversight); control group receives usual care for 12 months.

Main Results:

  • Primary outcome: proportion achieving triple risk factor control at 12 months.
  • Secondary outcomes: changes in clinical, behavioral, usability, and economic measures.
  • Analysis will follow intention-to-treat principles with multiple imputation for missing data.

Conclusions:

  • The trial will provide evidence on the clinical and cost-effectiveness of the CardioCare system.
  • Findings may support scaling the intervention in health checkup centers.
  • Results could inform national strategies for chronic disease management.
Abstract

Keywords:
cardiovascular diseasesdigital healthmedication adherencerandomized controlled trialrisk factor control

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
296
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
267
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
575
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
200
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
226
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
578